Pharmacogenomics (PGx) can enhance the accuracy of targeting patient therapy by enabling the use of an individual’s genome to assist predict drug response and guide optimal drug and dose selection. Ultimately, the goal is to provide safer, more impactful, and cost-effective treatment in patient therapy. Traditionally, pharmacogenomics is implemented reactively when there is a need to prescribe a high-risk drug. This is often expensive and suffers from a slow turnaround time. The field now recognizes the results and recommendations from pharmacogenomic profiling should be available preemptively in electronic health records and drug prescription systems.

The AgriType™ Targeted Genotyping by Sequencing Solution is designed and developed to address large-scale genotyping projects in agrigenomics (the application of genomics in the field of agriculture). The AgriType™ solution is powered by an advanced primer design algorithm and an efficient ultra-high multiplex PCR-based target enrichment chemistry. AgriType genotyping by sequencing provides a cost-effective solution to construct NGS libraries to quickly and efficiently screen hundreds to tens of thousands of markers of interest to accelerate genotyping studies in fields such as aquaculture, livestock farming, and seed breeding.

CleanPlex® Custom NGS Amplicon Panels are powered by Paragon Genomics’ CleanPlex NGS Amplicon Sequencing Technology – an ultra-high multiplex PCR-based target enrichment technology for next-generation sequencing (NGS). It features a highly advanced proprietary primer design algorithm and an innovative, patented background cleaning chemistry. Together, they allow CleanPlex Custom NGS Amplicon Panels to break the limits of existing target enrichment technologies (Read this blog article about how).

The AgriType™ Targeted Genotyping by Sequencing Solution is designed and developed to address large-scale genotyping projects in agrigenomics (the application of genomics in the field of agriculture). The AgriType™ solution is powered by an advanced primer design algorithm and an efficient ultra-high multiplex PCR-based target enrichment chemistry. AgriType genotyping by sequencing provides a cost-effective solution to construct NGS libraries to quickly and efficiently screen hundreds to tens of thousands of markers of interest to accelerate genotyping studies in fields such as aquaculture, livestock farming, and seed breeding.

The CleanPlex Pharmacogenomics Kit offers a simple and streamlined workflow. Starting from purified and quantitated DNA, the multiplex PCR-based protocol can be completed in just 3 hours, with 75 minutes of hands-on time, using a three-step workflow with minimal tube-to-tube transfers. Each step consists of a thermal cycling or incubation condition, followed by “with bead” purification using magnetic beads.

Identification of individuals with a suspected heritable cancer can lead to additional evaluation and help formulate prevention and treatment strategies. New guidelines published by the American Society of Breast Surgeons now recommend genetic testing for all breast cancer patients to determine hereditary risk in addition to standard imaging exams. In addition, the new guidelines also recommend re-evaluating breast cancer patients for any new breast cancer linked-genes. Next-generation sequencing (NGS) using targeted NGS panels is a cost-effective method to assess heritable cancer risk. Amplicon-based NGS assays have the advantage of simpler and shorter workflows that can be easily adopted to produce reliable results for cancer genetics research. However, not all amplicon-based target enrichment technologies can interrogate the increasingly large number of genes associated with cancer risk in a single assay. Therefore, care must be taken when selecting the appropriate technology for assay development.

Artemisinin-based combination therapies (ACTs) are the cornerstone of malaria treatment. However, artemisinin partial resistance has emerged that is characterized by slower parasite clearance times in patients following treatment with ACTs. Although the partner drugs in ACTs continue to be effective, this resistance threatens to undermine the gains made in malaria control. The emergence of drug-resistant malaria strains highlights the necessity for ongoing surveillance and the development of new therapeutic strategies. Resistance to ACTs can lead to increased malaria morbidity and mortality if not managed effectively.